블로그

• Lapatinib [T0078][Cas No. 231277-92-2]_TargetMol - 코아사이언스 Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer Lapatinib Inhibits Breast Cancer Cell Proliferation by Influencing PKM2 Expression. blog.naver.com · 2026.07.16
• Delphinidin chloride [TN1567][Cas No. 528-53-0]_TargetMol - 코아사이언스 Negative Breast Cancer Cell Lines. Breast Cancer (Auckl). 2011;5:143-154. 2.Aiyer HS, et al. blog.naver.com · 2026.06.10
• [ASCO2026] 삼중음성유방암(TNBC)의 새로운 표준, 이중항체 ADC '이잘론타맙 브렌기테 삼중음성유방암(TNBC) 치료의 패러다임 변화 삼중음성유방암(Triple-Negative Breast Cancer, TNBC)은 유방암 중에서도 가장 공격적이고 치료가 어려운 아형으로 에스트로겐 수용체(ER), 프로게스테론 수용체(PR), 그리고 HER2 수용체가 모두 발현되지 않아 기존의 효과적인 표적 치료제나 호르몬 요법의 혜택을 받지 못하기 때문입니다. blog.naver.com · 2026.06.09
• MRI로 항암치료 ‘횟수 줄이기’ 가능할까? HER2+ 유방암 TRAIN-3 연구가 던진 질문 논문제목: HER2 양성 조기 유방암에서 MRI를 통한 선행 항암화학요법 기간 맞춤화(TRAIN-3): 다기관, 단일군, 2상 임상 연구의 주요 결과 MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results blog.naver.com · 2026.04.10
• Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer Abstract Among women − breast cancer. blog.naver.com · 2025.11.02
• 유방암에 식이요법이 필요한이유 삼중음성유방암(TNBC, Triple-Negative Breast Cancer) 환우에게 맞춤 식이지도가 왜 도움이 되는지, 근거와 이유를 중심으로 정리해 드리겠습니다. 삼중음성유방암 식이지도가 도움이 되는 이유 영양 상태 유지와 면역력 강화 삼중음성유방암은 호르몬 수용체가 없고 HER2 단백질도 발현되지 않아 공격적이고 재발 위험이 높은 암입니다. blog.naver.com · 2025.12.03
• Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find ... find them Abstract CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR + HER2 negative (HER2-) metastatic breast cancer (BC) when combined with endocrine therapy. blog.naver.com · 2025.11.09
• Phase III Trial Results Suggest a New Standard of Care in Metastatic HER2-Positive Breast Cancer Phase III Trial Results Suggest a New Standard of Care in Metastatic HER2-Positive Breast Cancer In the -positive breast cancer, reported Sara M. blog.naver.com · 2025.06.27
• Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in ... with metastatic breast cancer Background HER2-targeted antibody–drug conjugates (ADCs) have revolutionized Hence, this study aims to identify factors predicting sensitivity to HER2 ADC in metastatic breast cancer blog.naver.com · 2025.08.04
• Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer Breast cancer is the most common cancer in women, and the first-line treatment for patients with hormone-receptor positive/HER2-negative metastatic breast cancer is CDK4/6 inhibitor plus endocrine therapy. blog.naver.com · 2025.07.08

블로그 결과 더보기 →